Biocept to Release Second Quarter 2019 Financial Results and Host Investor Conference Call on August 12, 2019

Date : 08/05/2019 @ 12:05PM
Source : PR Newswire (US)
Stock : Biocept Inc (BIOC)
Quote : 0.67  0.0 (0.00%) @ 6:49PM

Biocept to Release Second Quarter 2019 Financial Results and Host Investor Conference Call on August 12, 2019

Biocept (NASDAQ:BIOC)
Historical Stock Chart

6 Months : From May 2019 to Nov 2019

Click Here for more Biocept Charts.

SAN DIEGO, Aug. 5, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will release financial results for the three and six months ended June 30, 2019 after the market closes on Monday, August 12, 2019. The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

Biocept Logo (PRNewsFoto/Biocept, Inc.)

Individuals interested in participating on the conference call may do so by dialing (855) 656-0927 for domestic callers, (855) 669-9657 for Canadian callers, or (412) 902-4109 for other international callers. Those interested in listening to a webcast of the live conference call may do so by visiting https://www.webcaster4.com/Webcast/Page/1271/31194.

A replay of the conference call will be available for 48 hours following the conclusion of the call by dialing (877) 344-7529 for domestic callers, (855) 669-9658 for Canadian callers, or (412) 317-0088 for other international callers, and entering the replay access code 10133829. A webcast replay will be available for 90 days at http://ir.biocept.com/events.cfm.

About Biocept
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in plasma (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.

Investor Contact:
LHA Investor Relations
Jody Cain
Jcain@lhai.com
310-691-7100

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/biocept-to-release-second-quarter-2019-financial-results-and-host-investor-conference-call-on-august-12-2019-300895443.html

SOURCE Biocept, Inc.

Copyright 2019 PR Newswire

Latest BIOC Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.